Abstract
Summary What is known and Objective Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). Case summary A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. What is new and conclusion There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 175-176 |
| Number of pages | 2 |
| Journal | Journal of Clinical Pharmacy and Therapeutics |
| Volume | 38 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- adverse effect
- adverse event
- pazopanib
- posterior reversible encephalopathy syndrome
Fingerprint
Dive into the research topics of 'Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS